The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) today will present updated interim results from its ongoing Phase 1/2 study of MRT-2359 in patients with metastatic castration-resistant prostate ...
Shares of Monte Rosa TherapeuticsGLUE surged to a nearly four-year high Tuesday after the biotech company said all four patients in a prostate cancer study responded to its experimental treatment.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. MRT-2359 is an investigational, orally bioavailable, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results